144 related articles for article (PubMed ID: 24863682)
21. High serum levels of vascular endothelial growth factor-A and transforming growth factor-β1 before neoadjuvant chemoradiotherapy predict poor outcomes in patients with esophageal squamous cell carcinoma receiving combined modality therapy.
Cheng JC; Graber MS; Hsu FM; Tsai CL; Castaneda L; Lee JM; Chang DT; Koong AC
Ann Surg Oncol; 2014 Jul; 21(7):2361-8. PubMed ID: 24623035
[TBL] [Abstract][Full Text] [Related]
22. Adjuvant chemotherapy after esophagectomy: is there a role in the treatment of the lymph node positive thoracic esophageal squamous cell carcinoma?
Lyu X; Huang J; Mao Y; Liu Y; Feng Q; Shao K; Gao S; Jiang Y; Wang J; He J
J Surg Oncol; 2014 Dec; 110(7):864-8. PubMed ID: 24976079
[TBL] [Abstract][Full Text] [Related]
23. Risk of radiation pneumonitis in patients receiving taxane-based trimodality therapy for locally advanced esophageal cancer.
Shaikh T; Churilla TM; Monpara P; Scott WJ; Cohen SJ; Meyer JE
Pract Radiat Oncol; 2016; 6(6):388-394. PubMed ID: 27025161
[TBL] [Abstract][Full Text] [Related]
24. [Chemoradiotherapy using platinum analogs/5-FU for advanced esophageal cancer].
Shibata S; Kawasaki H; Nakai M; Morohashi H; Matsuya H; Yamada K; Morita T; Sasaki M
Gan To Kagaku Ryoho; 2002 Nov; 29(12):2209-12. PubMed ID: 12484039
[TBL] [Abstract][Full Text] [Related]
25. Combined-modality therapy for esophageal cancer: phase I trial of escalating doses of paclitaxel in combination with cisplatin, 5-fluorouracil, and high-dose radiation before esophagectomy.
Weiner LM; Colarusso P; Goldberg M; Dresler C; Coia LR
Semin Oncol; 1997 Dec; 24(6 Suppl 19):S19-93-S19-95. PubMed ID: 9427276
[TBL] [Abstract][Full Text] [Related]
26. A retrospective comparison of docetaxel and paclitaxel for patients with advanced or recurrent esophageal cancer who previously received platinum-based chemotherapy.
Mizota A; Shitara K; Kondo C; Nomura M; Yokota T; Takahari D; Ura T; Muro K
Oncology; 2011; 81(3-4):237-42. PubMed ID: 22094594
[TBL] [Abstract][Full Text] [Related]
27. Nodal metastasis from locally advanced esophageal cancer: how neoadjuvant therapy modifies their frequency and distribution.
Castoro C; Scarpa M; Cagol M; Ruol A; Cavallin F; Alfieri R; Zanchettin G; Rugge M; Ancona E
Ann Surg Oncol; 2011 Dec; 18(13):3743-54. PubMed ID: 21556952
[TBL] [Abstract][Full Text] [Related]
28. Esophagectomy after concurrent chemoradiotherapy improves locoregional control in clinical stage II or III esophageal cancer patients.
Liao Z; Zhang Z; Jin J; Ajani JA; Swisher SG; Stevens CW; Ho L; Smythe R; Vaporciyan AA; Putnam JB; Walsh GL; Roth JA; Yao JC; Allen PK; Cox JD; Komaki R
Int J Radiat Oncol Biol Phys; 2004 Dec; 60(5):1484-93. PubMed ID: 15590179
[TBL] [Abstract][Full Text] [Related]
29. Trimodality treatment versus surgery alone for esophageal cancer. A stratified analysis with minimally invasive pretreatment staging.
Jiao X; Sonett J; Gamliel Z; Doyle A; Schuetz J; Greenwald B; Suntharalingam M; Krasna MJ
J Cardiovasc Surg (Torino); 2002 Aug; 43(4):531-7. PubMed ID: 12124569
[TBL] [Abstract][Full Text] [Related]
30. A comparison of carboplatin and paclitaxel with cisplatinum and 5-fluorouracil in definitive chemoradiation in esophageal cancer patients.
Honing J; Smit JK; Muijs CT; Burgerhof JGM; de Groot JW; Paardekooper G; Muller K; Woutersen D; Legdeur MJC; Fiets WE; Slot A; Beukema JC; Plukker JTM; Hospers GAP
Ann Oncol; 2014 Mar; 25(3):638-643. PubMed ID: 24492674
[TBL] [Abstract][Full Text] [Related]
31. Taxane-based or platinum-based combination chemotherapy given concurrently with radiation followed by surgery resulting in high cure rates in esophageal cancer patients.
Lopez A; Harada K; Chen HC; Bhutani MS; Weston B; Lee JH; Maru DM; Chin FW; Rogers JE; Thomas I; Amlashi FG; Blum-Murphy MA; Rice DC; Zhao M; Hofstetter WL; Nguyen Q; Ajani JA
Medicine (Baltimore); 2020 Feb; 99(9):e19295. PubMed ID: 32118743
[TBL] [Abstract][Full Text] [Related]
32. A highly active and tolerable neoadjuvant regimen combining paclitaxel, carboplatin, 5-FU, and radiation therapy in patients with stage II and III esophageal cancer.
van de Schoot L; Romme EA; van der Sangen MJ; Creemers GJ; van Lijnschoten G; van Driel OJ; Rutten HJ; Nieuwenhuijzen GA
Ann Surg Oncol; 2008 Jan; 15(1):88-95. PubMed ID: 17896144
[TBL] [Abstract][Full Text] [Related]
33. Prognostic factors in definitive radiochemotherapy of advanced inoperable esophageal cancer.
Semrau R; Herzog SL; Vallböhmer D; Kocher M; Hölscher AH; Müller RP
Dis Esophagus; 2012 Aug; 25(6):545-54. PubMed ID: 22133297
[TBL] [Abstract][Full Text] [Related]
34. Incidence of brain metastases after trimodality therapy in patients with esophageal or gastroesophageal cancer: implications for screening and surveillance.
Wadhwa R; Taketa T; Correa AM; Sudo K; Campagna MC; Blum MA; Komaki R; Skinner H; Lee JH; Bhutani MS; Weston B; Maru DM; Rice DC; Swisher S; Hofstetter WL; Ajani JA
Oncology; 2013; 85(4):204-7. PubMed ID: 24051869
[TBL] [Abstract][Full Text] [Related]
35. Adjuvant sunitinib following chemoradiotherapy and surgery for locally advanced esophageal cancer: a phase II trial.
Horgan AM; Darling G; Wong R; Guindi M; Liu G; Jonker DJ; Lister J; Xu W; MacKay HM; Dinniwell R; Kim J; Pierre A; Shargall Y; Asmis TR; Agboola O; Seely AJ; Ringash J; Wells J; Marginean EC; Haider M; Knox JJ
Dis Esophagus; 2016 Nov; 29(8):1152-1158. PubMed ID: 26663741
[TBL] [Abstract][Full Text] [Related]
36. Phase II study of use of a single cycle of induction chemotherapy and concurrent chemoradiotherapy containing capecitabine/cisplatin followed by surgery for patients with resectable esophageal squamous cell carcinoma: long-term follow-up data.
Koo DH; Park SI; Kim YH; Kim JH; Jung HY; Lee GH; Choi KD; Song HJ; Song HY; Shin JH; Cho KJ; Yoon DH; Kim SB
Cancer Chemother Pharmacol; 2012 Mar; 69(3):655-63. PubMed ID: 21968953
[TBL] [Abstract][Full Text] [Related]
37. Outcomes of preoperative chemotherapy with docetaxel, cisplatin, and 5-fluorouracil followed by esophagectomy in patients with resectable node-positive esophageal cancer.
Watanabe M; Baba Y; Yoshida N; Ishimoto T; Nagai Y; Iwatsuki M; Iwagami S; Baba H
Ann Surg Oncol; 2014 Sep; 21(9):2838-44. PubMed ID: 24715216
[TBL] [Abstract][Full Text] [Related]
38. Trimodality therapy without a platinum compound for localized carcinoma of the esophagus and gastroesophageal junction.
Ajani JA; Correa AM; Walsh GL; Komaki R; Lee JH; Vaporciyan AA; Rice DC; Yao JC; Maru DM; Hofstetter WL; Phan AT; Swisher SG
Cancer; 2010 Apr; 116(7):1656-63. PubMed ID: 20143431
[TBL] [Abstract][Full Text] [Related]
39. Patterns of recurrence after trimodality therapy for esophageal cancer.
Dorth JA; Pura JA; Palta M; Willett CG; Uronis HE; D'Amico TA; Czito BG
Cancer; 2014 Jul; 120(14):2099-105. PubMed ID: 24711267
[TBL] [Abstract][Full Text] [Related]
40. [Concurrent standard dose of cisplatin, paclitaxel, and radiotherapy followed by surgery in treatment of thoracic esophageal carcinoma].
Jiang YY; Wu SX; Zhang P; Xie CY; Wang J; Sun CC
Zhonghua Yi Xue Za Zhi; 2008 Aug; 88(31):2171-4. PubMed ID: 19080664
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
